3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,4-triazol-1-yl-propionic acid ethyl ester | 501031-84-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,4-triazol-1-yl-propionic acid ethyl ester
• 英文别名: Ethyl 3-[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propyl]phenyl]-2-(1,2,4-triazol-1-yl)propanoate
• CAS: 501031-84-1
• 化学式: C₂₆H₂₈N₄O₃
• 分子量: 444.533
• InChiKey: VSNMVWVSPSLDKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  83
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,4-triazol-1-yl-propionic acid ethyl ester 以72%的产率得到3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,4-triazol-1-yl-propionic acid
  参考文献：
  名称：

  Antidiabetic agents

  摘要：

  本发明提供了式(I)的化合物： 1 其中A、X、Q、Y、B、D、Z和E具有规范中定义的任何值，以及药用可接受的盐，这些化合物作为抗糖尿病药是有用的。还公开了包含一个或多个式I化合物的药物组合物，制备式I化合物的方法，以及用于制备式I化合物的中间体。

  公开号：

  US20030171377A1
• 作为产物：
  描述：

  4-[3-(9-Borabicyclo[3.3.1]nonan-9-yl)propyl]-5-methyl-2-phenyl-1,3-oxazole 、 ethyl 3-(4-bromophenyl)-2-(1H-1,2,4-triazol-1-yl)propanoate 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 三苯胂 、 caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 以0.492 g的产率得到3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,4-triazol-1-yl-propionic acid ethyl ester
  参考文献：
  名称：

  Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARα/γ dual agonists

  摘要：

  The synthesis of a new series of phenylpropanoic acid derivatives incorporating an heteroaryl group at the alpha-position and their evaluation for binding and activation of PPAR alpha and PPAR gamma are presented in this report. Among the new compounds, (S)-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,3- triazol-2-yl-propionic acid (17j), was identified as a potent human PPAR alpha/gamma dual agonist (EC50 = 0.013 and 0.061 mu M, respectively) with demonstrated oral bioavailability in rat and dog. 17j was shown to decrease insulin levels, plasma glucose, and triglycerides in the ZDF female rat model. In the human apolipoprotein A-1/CETP transgenic mouse model 17j produced increases in hApoA1 and HDL-C and decreases in plasma triglycerides. The increased potency for binding and activation of both PPAR subtypes observed with 17j when compared to previous analogs in this series was explained based on results derived from crystallographic and modeling studies. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.09.001

文献信息

• Antidiabetic agents
  申请人：——

  公开号：US20030171377A1

  公开（公告）日：2003-09-11

  The present invention provides compounds of Formula (I): 1 wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.

  本发明提供了式(I)的化合物： 1 其中A、X、Q、Y、B、D、Z和E具有规范中定义的任何值，以及药用可接受的盐，这些化合物作为抗糖尿病药是有用的。还公开了包含一个或多个式I化合物的药物组合物，制备式I化合物的方法，以及用于制备式I化合物的中间体。
• Oral antidiabetic agents
  申请人：Warner-Lambert Company LLC

  公开号：EP1577305A1

  公开（公告）日：2005-09-21

  The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein:    A is    X is CH2-CH2-O or -CH2CH2CH2-;    Q is    Y is CH2;    Z is absent;    B is H;    D is H, and E is CO2H; that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising compounds of formula (I).

  本发明提供了式 (I) 的化合物 或其药学上可接受的盐，其中 A 是 X是CH2-CH2-O或-CH2CH2CH2-； Q 是 Y 是 CH2 Z 不存在； B 是 H； D 是 H、 和 E 是 CO2H； 可用作抗糖尿病药物。还公开了包含式（I）化合物的药物组合物。
• ORAL ANTIDIABETIC AGENTS
  申请人：Warner-Lambert Company LLC

  公开号：EP1423363A1

  公开（公告）日：2004-06-02
• [EN] ORAL ANTIDIABETIC AGENTS<br/>[FR] AGENTS ANTIDIABETIQUES ORAUX
  申请人：WARNER LAMBERT CO

  公开号：WO2003018553A1

  公开（公告）日：2003-03-06

  The present invention provides compounds of Formula (I): f I wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, process for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
• Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARα/γ dual agonists
  作者：Agustin Casimiro-Garcia、Christopher F. Bigge、Jo Ann Davis、Teresa Padalino、James Pulaski、Jeffrey F. Ohren、Patrick McConnell、Christopher D. Kane、Lori J. Royer、Kimberly A. Stevens、Bruce Auerbach、Wendy Collard、Christine McGregor、Kun Song

  DOI：10.1016/j.bmc.2009.09.001

  日期：2009.10

  The synthesis of a new series of phenylpropanoic acid derivatives incorporating an heteroaryl group at the alpha-position and their evaluation for binding and activation of PPAR alpha and PPAR gamma are presented in this report. Among the new compounds, (S)-3-4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,3- triazol-2-yl-propionic acid (17j), was identified as a potent human PPAR alpha/gamma dual agonist (EC50 = 0.013 and 0.061 mu M, respectively) with demonstrated oral bioavailability in rat and dog. 17j was shown to decrease insulin levels, plasma glucose, and triglycerides in the ZDF female rat model. In the human apolipoprotein A-1/CETP transgenic mouse model 17j produced increases in hApoA1 and HDL-C and decreases in plasma triglycerides. The increased potency for binding and activation of both PPAR subtypes observed with 17j when compared to previous analogs in this series was explained based on results derived from crystallographic and modeling studies. (C) 2009 Elsevier Ltd. All rights reserved.